Free Trial
NYSE:PEN

Penumbra Q3 2026 Earnings Report

Penumbra logo
$317.24 +0.19 (+0.06%)
As of 02:12 PM Eastern
This is a fair market value price provided by Massive. Learn more.

Penumbra EPS Results

Actual EPS
N/A
Consensus EPS
$1.20
Beat/Miss
N/A
One Year Ago EPS
N/A

Penumbra Revenue Results

Actual Revenue
N/A
Expected Revenue
$401.41 million
Beat/Miss
N/A
YoY Revenue Growth
N/A

Penumbra Announcement Details

Quarter
Q3 2026
Time
After Market Closes
Conference Call Date
Wednesday, November 4, 2026
Conference Call Time
4:30PM ET

Conference Call Resources

Penumbra Earnings Headlines

The end may be near for these iconic stocks
Marc Chaikin, founder of Chaikin Analytics, says two forces - AI disruption and fracturing global trade - are triggering a historic wealth transfer already underway in 2026. Household names like Intuit (-57%), Boston Scientific (-49%), and Tractor Supply (-40%) are cratering, while lesser-known companies like Sandisk (+573%) and Rackspace (+444%) surge. Chaikin has identified specific stocks he believes investors should sell before they fall further - and the names may surprise you. He's also pinpointing a company tapped as Nvidia's self-driving partner and a potential AI megadeal that could split into three high-growth stocks. Stream his free presentation to get every buy and sell recommendation with no membership or credit card required.tc pixel
Incuvate Files Patent Infringement Lawsuit Against Penumbra
Penumbra: Q2 Earnings Snapshot
See More Penumbra Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like Penumbra? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Penumbra and other key companies, straight to your email.

About Penumbra

Penumbra (NYSE:PEN) is a medical device company that develops, manufactures and markets products used to treat vascular conditions and other serious medical disorders. The company is best known for its minimally invasive technologies designed to remove blood clots, restore blood flow and support the treatment of neurovascular conditions, including ischemic stroke.

Its product portfolio includes aspiration and thrombectomy systems, embolization devices, access and delivery systems, and other technologies used by physicians in neurointerventional and peripheral vascular procedures. Penumbra also develops products for treating aneurysms, arteriovenous malformations and selected conditions affecting blood vessels outside the brain.

Founded in 2004 and headquartered in Alameda, California, Penumbra serves hospitals and health care providers in the United States and international markets. The company’s products are distributed through a combination of direct sales and international distribution arrangements. Adam Elsesser is Penumbra’s chairman and chief executive officer.

View Penumbra Profile